Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Total revenues	$ 2,380	$ 2,639	$ 61,831	$ 69,393
Operating expenses:
Cost of revenue	50	38	161	1,967
Research and development	195,178	145,028	400,416	470,754
Selling, general and administrative	25,744	40,933	92,330	133,223
Restructuring, long-lived assets impairment and related charges	12,712	3,372	38,939	8,738
Total operating expenses	233,684	189,371	531,846	614,682
Loss from operations	(231,304)	(186,732)	(470,015)	(545,289)
Other income:
Change in fair value of equity investments	1,130	(2,707)	(4,356)	(20,896)
Interest income	17,527	21,931	57,656	66,254
Other (expense) income, net	(893)	882	(1,715)	(7,506)
Total other income	17,764	20,106	51,585	37,852
Loss before (provision for) benefit from income taxes	(213,540)	(166,626)	(418,430)	(507,437)
(Provision for) benefit from income taxes	(177)	3,213	1,059	8,293
Net loss	(213,717)	(163,413)	(417,371)	(499,144)
Net loss attributable to noncontrolling interest	0	0	0	(56)
Net loss attributable to Vir	$ (213,717)	$ (163,413)	$ (417,371)	$ (499,088)
Net loss per share attributable to Vir, basic (in USD per share)	$ (1.56)	$ (1.22)	$ (3.07)	$ (3.73)
Net loss per share attributable to Vir, diluted (in USD per share)	$ (1.56)	$ (1.22)	$ (3.07)	$ (3.73)
Weighted-average shares outstanding, basic (in shares)	136,653,753	134,289,620	136,058,223	133,969,878
Weighted-average shares outstanding, diluted (in shares)	136,653,753	134,289,620	136,058,223	133,969,878
Collaboration revenue
Revenues:
Total revenues	$ (1,102)	$ (4,387)	$ (2,034)	$ 28,408
Contract revenue
Revenues:
Total revenues	1,391	289	54,468	1,484
Grant revenue
Revenues:
Total revenues	$ 2,091	$ 6,737	$ 9,397	$ 39,501